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Precore and Core Promoter Mutations of the Hepatitis B Virus 
Gene in Chronic Genotype C -Infected Children
The precore (G1896A) and core promoter (A1762T, G1764A) mutations of the hepatitis B 
virus gene are known to be associated with changes in immunologic phase or the 
progression to complicated liver disease in adults. We analyzed these mutations in 
chronically HBV-infected children. Serum was collected from 37 children with chronic HBV 
infection from March 2005 to September 2008. HBV DNA extraction and nested PCR were 
followed by sequencing of the PCR products. The children were 6.7 ± 4.6 yr old. All of 37 
children had HBV genotype C. Of the cohort, 31 (83.8%) were HBeAg-positive and 6 
(16.2%) were HBeAg-negative; the former group comprised 18 (48.6%) who were in the 
immune-tolerance phase (ITP) and 13 (35.2%) in the immune-clearance  phase (ICP). Most 
of the patients had HBV DNA levels of > 1.0 × 10
8 copies/mL. In the ITP group, only 1 
(5.5%) had core promoter mutations, and none had the precore mutation. In the ICP 
group, only 2 (15.4%) had core promoter mutations; the remaining 6 patients had HBV 
DNA levels of < 2.0 × 10
3 copies/mL and no core promoter/precore mutations. The very 
low incidence of the precore/core promoter gene mutation, in children, suggests that 
these mutations may be the result of life-long chronic HBV infection. 
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INTRODUCTION
There are three phases in the natural history of chronic HBV in-
fection (1). The first is the immune-tolerant phase (ITP) defined 
by hepatitis B e antigen (HBeAg)-positive, normal hepatic en-
zyme levels and high serum HBV DNA concentrations. The sec-
ond is the immune-clearance phase (ICP) defined by HBeAg-
positive, abnormal hepatic enzyme levels and falling serum 
HBV DNA concentrations. The third is the HBeAg negative car-
rier stage defined by seroconversion from HBeAg to hepatitis B 
e antibody (HBeAb), normal hepatic enzyme levels and low or 
nondetectable serum HBV DNA concentrations. After the third 
phase, reactivation may develop. The progression from the first 
to the third or reactivation phase over several decades may cause 
the development of complications of chronic HBV infection, 
such as liver cirrhosis and hepatocellular carcinoma (2).
  Precore mutations, such as G1896A (guanine-to-adenine mu-
tation at nucleotide 1,896), and core promoter (CP) mutations, 
including A1762T (adenine-to-thymine mutation at nucleotide 
1,762) and G1764A (guanine-to-adenine mutation at nucleo-
tide 1,764), are known to be associated with HBeAg status in 
adults (3). The precore stop-codon mutation (G1896A) abolishes 
HBeAg and the dual mutation in the CP region (A1762T, G1764A) 
down-regulates HBeAg production. These mutations are also 
reported to be associated with change of the immunologic phase 
and the resulting severity of liver disease in adults with chronic 
HBV infection (4, 5). However, the causal relationship between 
these mutations and the change of the immunologic phase or 
severity of liver disease has not been established definitively. 
Some researchers have reported that these mutations are not 
related to either immunologic change or liver disease (1, 6).
  The aim of this study was to determine the incidence of pre-
core/CP mutations in relation to the change of the immunolog-
ic phase in young chronic infected children.
 
MATERIALS AND METHODS
Serum was collected from 37 children with chronic HBV infec-
tion who had been HBsAg-positive for over 6 months and had 
visited Jeju National University Hospital (JNUH), Jeju, Korea 
between March 2005 and September 2008. The number of blood 
sampling from each patient was 3 to 5 times matching to every 
visit to the pediatric clinic. Serum from patients who were tak-
ing antiviral agents, such as lamivudine or adefovir, was exclud-
ed from the analysis. All sera were immediately stored in a deep 
freezer at -80.0°C until required for analysis. We also recorded 
information regarding the patients’ serology, levels of aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), HBeAg/ 
HBeAb, and HBV DNA (copies/mL) in serum. 
  Normal serum AST and ALT level was defined when lower Kang HS, et al.  •  Precore and Core Promoter Mutations of the HBV Gene
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than 45 IU/L. Immune tolerant phase was defined by normal 
AST/AST level, HBeAg positive and high serum HBV DNA con-
centrations (7). The transient abnormal AST/ALT level caused 
by other viral infections was also clarified to this phase in our 
study. Immune clearance phase was defined by abnormal AST/
AST level, HBeAg positive and falling serum HBV DNA concen-
trations (7). Immune clearance phase was differentiated from 
the transient nonspecific hepatitis caused by other viral infec-
tion in the children. 
  HBV DNA levels were quantified by a polymerase chain reac-
tion (PCR) assay with a lower limit of detection of 2×10
2 copies/
mL and a linearity range of 2 × 10
2-2 × 10
5 copies/mL (Cobas 
Amplicor HBV Monitor, Roche Diagnostic Systems, Pleasanton, 
CA, USA). All HBeAg-positive samples were prediluted up to 
10
6-fold, and a 10
5-fold dilution was used for initial testing. 
  HBV DNA was extracted at room temperature from 200 μL 
aliquots of each child’s serum (thawed at 4.0°C) using the High 
Pure Viral Nucleic Acid Kit (Roche, Penzberg, Germany). The 
extracted HBV DNA was immediately used for genotyping and 
nested PCR.
  Using genotype-specific primers developed by Naito et al. (8), 
the nucleotide sequences of the pre-S1 through S genes were 
amplified. Genotyping was performed for only three (A-C) of 
the six (A-F) types. The first PCR was performed using universal 
primers, including P1 and S1-2, and was followed by a second 
PCR, which was performed using the primer mixtures specify-
ing different genotypes, including A, B, and C. Finally, genotyp-
ing was performed based on the band sizes (type A, 281 bp; type 
B, 122 bp; and type C, 68 bp) shown on electrophoresis (data 
not shown).
  The tube for the first PCR of the precore and CP genes was 
prepared using 50 μL aliquots of mixtures containing 10 μL of 
extracted HBV DNA, 1 μL of 10 pM of external primers, each of 
the four dNTPs at 0.2 mM, 1.5 mM MgCl2, 1 U of Taq polymerase, 
5 μL of 10 LPCR buffer (Promega, Madison, WI, USA), and 32 μL 
of nuclease-free water. The external primers were P1 (5´-CATA-
AGAGGACTCTTGGACT-3´, positions 1,653-1,672) and P2 (5´- 
GGAAAGAAATCAGAAGGCA-3´, positions 1,974-1,956). The 
mixture for the first PCR was put into the thermocycler and the 
following PCR protocol used: denaturation at 94.0°C for 5 min; 
followed by 40 cycles of denaturation at 94.0°C for 30 sec, an-
nealing at 54.0°C, and extension at 72.0°C for 45 sec; with a final 
extension at 72.0°C for 10 min.
  The tube for the second PCR was prepared using the 50 μL of 
mixture comprising the first PCR product, 1 μL of 10 pM of in-
ternal primers, 0.2 mM of each of the four dNTPs, 1.5 mM MgCl2, 
1 U of Taq polymerase, 5 μL of 10 LPCR buffer (Promega), and 
40 μL of nuclease-free water. The internal primers were P3 (5´- 
GGACTCTTGGACTCTCAGCAA-3´, positions 1,660-1,680) and 
P4 (5’-TCCACAGAAGCTCCAAATTCTTT-3´, positions 1,941-
1,919). The protocol for the second PCR was the same as for the 
first. The final PCR products were identified on electrophoresis 
carried out using 1.0% agarose gel stained with ethidium bro-
mide.
  Finally, the second PCR product was sequenced using an ABI 
PRISM BigDye Terminator v3.1 cycle sequencing kit (Applied 
Biosystems, Foster City, CA, USA) and then analyzed using a 
genetic analyzer (ABI PRISM 3100, Applied Biosystems). The 
PCR products, which included 4 μL of Terminator Ready Reac-
tion Mix, 1 μL of cleaned PCR product (20-40 ng of PCR prod-
uct), 1 μL of primer (5 pM), and sterile water to a total volume 
of 10 μL, was placed in a reaction tube. Cycle sequencing was 
then carried out as follows: 30 cycles of 96.0°C for 10 sec, 50.0°C 
for 5 sec, and 60.0°C for 4 min. Precipitation and loading of the 
samples were then performed according to the manufacturer’s 
instructions.
  Results are expressed as the mean ± standard deviation (range). 
Differences between categorical variables were analyzed using 
chi-squared test. Kruskal-Wallis test was used for continous vari-
ables according to 3 immunologic phases. A P value of less than 
0.05 (two-tailed) was considered statistically significant.
Ethics statement
This study was reviewed and approved by the institutional re-
view board of Jeju National University Hospital (JNUH-IRB-07- 
16). We received written informed consent from the parents of 
all participating children.
 
RESULTS
Among the 37 children with chronic HBV infections (age 6.7 ± 
4.6 yr, mean ± SD; range 10 months-15.8 yr), vertical infection 
was the most common route of infection (n = 31, 83.8%), followed 
by another member of the family (n = 3, 8.1%); the origin of in-
fection was unknown in three patients (8.1%). 
  Of the cohort, 18 patients (48.6%) were in the ITP, with high 
viral replication and normal ALT levels (Table 1), and 13 (35.2%) 
were in the ICP, with viral replication and elevated ALT levels. 
Six patients (16.2%) were in the HBeAg negative carrier state 
(Table 1). There was no significant association between gender 
and immunologic phase (P = 0.189, chi-squared test). The mean 
age was highest in the HBeAg negative carrier group, followed 
by the ICP and ITP groups (Table 1). 
  Hepatic enzyme levels, including AST and ALT, were all near 
the upper limit of normal in the ITP group, three or five times 
the upper limit of normal in the ICP group, and near the lower 
limit of normal in those in the HBeAg negative carrier state. The 
distribution of the two hepatic enzymes differed significantly 
between the three immunologic phase groups (P < 0.001, Krus-
kal-Wallis test; Table 1).
  In the ITP and ICP groups, most patients had high HBV DNA 
levels (i.e., more than 1.0 × 10
8 copies/mL). In the HBeAg nega-Kang HS, et al.  •  Precore and Core Promoter Mutations of the HBV Gene
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tive carrier group, all of the patients had low HBV DNA levels 
(range 10
2-10
5 copies/mL; Table 1). The distribution of HBV DNA 
levels differed significantly between the groups (P < 0.001, chi-
squared test; Table 1).
  All of the 37 patients had HBV genotype C. Only 3 of the 37 
patients exhibited CP mutations. Only one (5.5%) of the 18 ITP 
patients had the G1764A mutation and 1 had the A1762T/G1764A 
mutation (Table 2). Of the 13 patients in the ICP group, only two 
(15.4%) exhibited CP mutations, including one A1762T/G1764A 
mutation. None of the patients in the HBeAg negative carrier 
group had any CP mutations.
  Only one of the entire cohort exhibited a precore mutation: an 
ICP patient (7.7%). The distributions of both the precore and CP 
mutations did not differ significantly (A1762T, P = 0.788; G1764A, 
P = 0.447; G1896A, P = 0.387, chi-squared test; Table 2).
 
DISCUSSION
Precore and CP gene mutations frequently occur over several 
decades of chronic HBV infection. The common mutations of 
the CP genes are the adenine-to-thymine mutation at nucleo-
tide 1762 (A1762T) and/or the guanine-to-adenine mutation at 
nucleotide 1764 (G1764A) (9-11). In the precore gene, the gua-
nine-to-adenine mutation at nucleotide 1896 (G1896A) is the 
most prevalent (3, 11).
  There are many conflicting reports regarding the association 
between these gene mutations and disease severity in chronic 
HBV infection, with progression from the immune tolerant phase 
to the HBeAg negative carrier or reactivation phase (12). There 
are some reports that precore/CP mutations are correlated with 
the patient’s immunological and/or disease status (4, 5, 13-17), 
but others that those mutations have no significant correlation 
with viral replication or liver damage (1, 6).
  The prevalence of CP mutations is higher than that of precore 
mutations (4) among Koreans, in whom only the C genotype       
is expressed (18). In Korean adults (4), CP mutations (A1762T, 
G1654A) were found in 95.0% of ICP patients, in 67% of HBeAg 
negative carriers, and in 30.0% of ITP patients. The precore mu-
tation (G1896A) was less prevalent than CP mutations (i.e., 5% 
of ICP patients, 32.5% of HBeAg negative carriers, and 22.5% of 
ITP patients). In Taiwanese adults with HBeAg negative chronic 
hepatitis B (19), the overall prevalence of the precore stop codon 
mutant and basal core promoter mutant was 67% and 60%, re-
spectively. Genotype B and C are major strains in Taiwan.
  In German adults with HBeAg negative chronic hepatitis B 
(20), the overall prevalence of the precore stop codon mutant 
and basal core promoter mutant was 46% and 59%, respective-
ly. Genotype A and D are major strains in Germany. In the anal-
ysis of these mutation rates of 3 countries, it seems to be similar 
results in HBeAg negative carriers.
  Compared with reports in Korean adults (4), the CP mutation 
rate of our study was very low: 9.1% of the ITP group, 11.1% of 
the ICP, and 0% of those in the HBeAg negative carrier state. The 
incidence of the precore mutation was extremely low (4.1%), and 
was found only in the ITP group. There are a few reports associ-
ated with precore or core promoter mutation of HBV in chronic 
infected children in other countries (21-24). In the analysis for 
89 sera from 32 chronic HBV infected Taiwanese children (24), 
precore stop codon mutant was found in 10%-25% of children 
before HBeAg seroconversion and in 39% of children after sero-
conversion. Core promoter mutations rates of Taiwanese chil-
dren (22) were 9.1% in seroconverters (HBeAg negative carrier) 
and 5.5% in the nonseroconverters. In the analysis of 155 Euro-
pean children (21), 2 (2.2%) of 90 HBeAg positive patients and 5 
Table 1. Baseline characteristics of the 37 patients with chronic hepatitis B virus 
(HBV) infection
Variables
HBeAg+ HBeAg-
ITP  
(n = 18)
ICP  
(n = 13)
Inactive carrier  
(n = 6) 
Sex, M/F* 12/6 8/5 2/4
Age (yr)
†   5.1± 4.5
¶   7.5 ± 3.9 10.1 ± 4.6
AST (IU/L)
‡ 40.6 ± 17.7
¶ 103.9 ± 78.9   28.2 ± 10.0
ALT (IU/L)
§ 40.6 ± 22.1
¶   170.5 ± 162.9 17.2 ± 6.3
HBV DNA (copies/mL)
||
   High (n)
   Moderate (n)
   Low (n)
   Negative (n)
 
16
  1
  1
  0
 
9
4
0
0
 
0
0
6
0
*P = 0.189 (χ2 test); 
†P = 0.061 (Kruskal-Wallis test);
‡P < 0.001 (Kruskal-Wallis test); 
§P < 0.001 (Kruskal-Wallis test); 
||P ≤ 0.001 (χ2 test); 
¶Mean ± 2SD. ITP, immune 
tolerance phase; ICP, immune clearance phase; AST, aspartate aminotransferase; ALT, 
alanine aminotransferase; high, > 10
8 copies/mL; moderate, 10
5-10
8 copies/mL; low, 
10
2-10
5 copies/mL; negative, < 10
2 copies/mL. From 3 to 5 samples of each patient, 
the highest value out of laboratory data and the value at the time of mutation were 
selected in the patients without and with precore/core gene mutation, respectively.
Table 2. Distribution of genotypes and precore/CP gene mutations in relation to the 
clinical status of chronic HBV infection
Variables
HBeAg+ HBeAg- 
ITP  
(n = 18)
ICP  
(n = 13)
Inactive carrier 
(n = 6)
Genotype C 18 (100%) 13 (100%) 6 (100%)
CP mutations, No. (%)    
   nt 1762*
      wild
      mutant
 
17
  1
 
12
  1
 
6
0
   nt 1764
†
      wild
      mutant
 
17
  1
 
11
  2
 
6
0
   nt 1762/1764
      wild
      mutant
 
17
  1
 
12
  1
 
6
0
Overall mutations 1 (5.5%) 2 (15.4%) 0 (0%)
Precore mutations, No. (%)
   nt 1896
‡
      wild
      mutant
 
18
  0
 
12
  1
 
6
0
   Overall mutations 0 (0%) 1 (7.7%) 0 (0%)
*P = 0.788 (χ2 test); 
†P = 0.447 (χ2 test); 
‡P = 0.387 (χ2 test). nt, nucleotide.Kang HS, et al.  •  Precore and Core Promoter Mutations of the HBV Gene
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(7.7%) of 65 anti-HBe positive children had precore stop codon 
mutation. 
  In the HBeAg negative carriers, the mutation rates of precore 
stop codon and basal core promoter genes are high in adult and 
low in children. This wide disparity suggest that these mutations 
may be the result of life-long chronic HBV infection. 
  These low mutation rates in our study may originate from the 
mutated HBV gene of the patient’s mother when the patient 
was born. Unfortunately, the incidence of these gene mutations 
in the mothers of all 37 children was not analyzed. The actual 
mutation rate of these genes may thus be nearly 0%, despite the 
changes in immunologic phase. These findings suggest that pre-
core/CP mutation is a only secondary occurrence, and not the 
cause of immunological change in patients with chronic HBV 
infection. These findings also support the opinion of Chang et 
al. (24), who stated that “The precore stop codon mutant is se-
lected by host immune pressure, but is not an initiator of the loss 
of immune tolerance during chronic HBV infection in children” .
  Although HBeAg seroconversion is estimated to be affected 
by age (Table 1), the age distribution did not differ significantly 
with the immunologic phase (P = 0.061, Kruskal-Wallis test). This 
may be due to the small size of each group and the wide stan-
dard deviations.
  There are limitations in our study. The first is small sample size. 
The second is that direct sequencing of DNA samples of nested 
PCR performed in our study reflects the major strains of HBV. It 
is possible that the prevalence of precore/core promoter gene 
mutation in these samples is underestimated when the mutant 
strains are minor strains. HBV viral quasi-species evolution in 
the precore/core gene before and after HbeAg seroconversion 
in chronic HBV infected patients was reported (25). They sug-
gested that the high viral diversity, including the entire mutant 
strains, may be associated with the change from the immune 
tolerance pahse to the immune clearance phase (25). 
  HBeAg-negative chronic hepatitis B, which represents the 
reactivation phase, is common in adults and is associated with 
a high prevalence of precore/CP mutations (26). However, as 
confirmed in the present study, this type is rare in children (27).
  The geographical distribution of HBV genotypes reveals a high 
prevalence of genotypes B and C in East Asia (12, 28, 29), and 
countries that have many immigrants of East Asiatic origin, such 
as Canada (30). Only genotype C was found in previous Korean 
studies (18, 28). In our study, all 37 patients had genotype C.
  In conclusion, the very low incidence of the precore/core pro-
moter gene mutation, in children, suggests that these mutations 
may be the result of life-long chronic HBV infection.  
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The precore (G1896A) and core promoter (A1762T, G1764A) mutations of the hepatitis B virus gene are known to be associated 
with changes in immunologic phase or the progression to complicated liver disease in adults. In contrast to the high mutation 
rates in adults, our study in children revealed the very low mutation rates of precore and core promoter gene. Such results suggest 
that these mutations may be the result of life-long chronic HBV infection.